Skip to main content
BF Biosciences Limited logo

BF Biosciences Limited - Investor Relations & Filings

Listed
Ticker · BFBIO ISIN · PK0148201012 PSX Manufacturing
Open in API
Filings indexed 36 across all filing types
Latest filing 2025-10-21 Regulatory Filings
Country PK Pakistan
Listing PSX BFBIO · 1 venue

About BF Biosciences Limited

http://bfbio.com/

BF Biosciences Limited is a pioneering biotech pharmaceutical company engaged in the import, manufacturing, marketing, and distribution of pharmaceutical products. The company specializes in state-of-the-art biotechnology, offering life-saving drugs for conditions such as cardiovascular diseases, breast cancer, diabetes mellitus, chronic kidney diseases, and rheumatoid arthritis. Operating as a joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina, BF Biosciences serves markets including Pakistan, Nepal, Afghanistan, and other international regions, built upon a foundation of trust and credibility.

Recent filings

Filing Released Lang Actions
Annual Progress Report for the Year Ended June 30, 2025
Regulatory Filings Classification · 90% confidence The document is an 'Annual Progress Report' submitted by BF Biosciences Limited to the Pakistan Stock Exchange. It includes an 'Agreed-Upon Procedures Report' from KPMG regarding the utilization of IPO funds and project implementation status. While it contains financial data related to project expenditures, it is not a full annual financial report (10-K) or an interim financial report (IR). Instead, it functions as a regulatory compliance filing detailing the post-issue reporting requirements for an IPO. Given the specific nature of the report (post-issue progress and audit of procedures), it falls under the category of regulatory filings.
2025-10-21 English
Material Information
Regulatory Filings Classification · 95% confidence The document is a formal notification from BF Biosciences Limited to the Pakistan Stock Exchange regarding the launch of a new product, Zeptide. It cites specific regulatory sections (Sections 96 and 131 of the Securities Act, 2015) for disclosing 'Material Information'. Since this is a general regulatory disclosure of corporate developments that does not fit into specific categories like earnings, dividends, or M&A, it falls under the RNS (Regulatory Filings) category.
2025-10-14 English
Transmission of Annual Financial Statements for the Year Ended 30-06-2025
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' and contains extensive content typical of a full annual report, including corporate information, board of directors, audit committee details, manufacturing and quality descriptions, product portfolio, strategic collaborations, financial data sections, auditor's report, and financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. The presence of detailed financial statements and auditor's report confirms it is a comprehensive yearly report covering company activity and financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2025-10-03 English
Notice of Annual General Meeting
AGM Information Classification · 100% confidence The document is a detailed notice of an Annual General Meeting (AGM) for BF Biosciences Limited, including the agenda, procedures for participation, proxy voting, and special business items such as approval of related party transactions. It contains no financial statements or detailed financial analysis itself but rather serves as an official notification and instructions for the AGM. The document length is substantial but it is clearly a meeting notice and not the actual annual report or financial statements. Therefore, it fits the category of AGM Information (AGM-R).
2025-10-03 English
Notice of Annual General Meeting prior to publication
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (AGM) for BF Biosciences Limited. It outlines the agenda for the meeting, including the adoption of financial statements, appointment of auditors, and special business regarding related party transactions. It also includes a ballot paper for postal voting. This document is intended to inform shareholders of the upcoming meeting and solicit their participation/votes, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2025-10-02 English
Financial Results for the Year Ended 30-06-2025
Annual Report Classification · 100% confidence The document contains comprehensive financial statements for BF Biosciences Limited for the year ended 30 June 2025, including the Statement of Financial Position, Statement of Profit or Loss, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows. It includes detailed notes (referenced as 1 to 47) and comparative data for 2024. Given the length (over 24,000 characters) and the inclusion of full audited-style financial statements for a complete fiscal year, this is classified as an Annual Report (10-K). FY 2025
2025-09-23 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.